Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
快速连接

白皮书

Tech sheet: Dr. Reddy's Bempedoic Acid API Offerings

2022

Tech sheet: Dr. Reddy's Bempedoic Acid API Offerings

Tech sheet: Dr. Reddys Olaparib API Offerings

2022

Tech sheet: Dr. Reddy's Olaparib API Offerings

Tech sheet: Dr. Reddy's Enzalutamide API Offerings

2022

Tech sheet: Dr. Reddy's Enzalutamide API Offerings

Semaglutide - Dr. Reddy’s Fully Synthetic Peptide API

2022

Semaglutide - Dr. Reddy’s Fully Synthetic Peptide API

Our Peptide API Capabilities and Services throughout the product life cycle

2022

Our Peptide API Capabilities and Services throughout the product life cycle

Tech Sheet - Dr. Reddy’s Eribulin Mesylate API offerings

2022

Tech Sheet - Dr. Reddy’s Eribulin Mesylate API offerings

Tech Sheet – Dr. Reddy’s Fexofenadine API offerings

2022

Tech Sheet – Dr. Reddy’s Fexofenadine API offerings

Tech Sheet - Dr. Reddy’s Azacitidine API offerings

2022

Tech Sheet - Dr. Reddy’s Azacitidine API offerings

Tech Sheet - Dr. Reddy’s Ramipril API offerings

2022

Tech Sheet - Dr. Reddy’s Ramipril API offerings

Tech Sheet - Dr. Reddy’s Gemcitabine API offerings

2021

Tech Sheet - Dr. Reddy’s Gemcitabine API offerings

Tech Sheet: Dr. Reddy’s Abiraterone Acetate API offerings

2021

Tech Sheet: Dr. Reddy’s Abiraterone Acetate API offerings

Remdesivir

2021

瑞德西韦（Remdesivir）系由瑞迪博士（Dr.Reddy’s）在吉利德（Gilead）许可下研发：

Whitepaper : Dr.Reddy's 2 DG- A promising treatment in hospitalized COVID-19 patients

2021

白皮书： 瑞迪博士的2 DG - 一种对住院的新冠病毒病患者来极具前景的治疗方法

Techsheet: Dr.Reddy's Lenvatinib API offerings

2021

技术表： 瑞迪博士的乐伐替尼（Lenvatinib）原料药产品

Meeting the New Regulatory Requirements in Sartan API Production

2019

满足沙坦（Sartan）原料药生产的新法规要求

ROXADUSTAT - a multipronged development strategy

2021

罗沙司他（ROXADUSTAT）- 多管齐下的发展战略

Dr.Reddy's Apremilast API and finished formulation offerings.

2021

瑞迪博士的阿普斯特片（Apremilast）原料药和成品配方产品。

Dr. Reddy’s Fosaprepitant API offerings

2021

瑞迪博士的福沙吡坦（Fosaprepitant）原料药产品

Apixaban API – ready-to-compress granules and finished dosage forms

2021

阿哌沙班（Apixaban）原料药 - 易压缩颗粒和成品剂型

Apalutamide API – an attractive NCE-1 opportunity for generic pharma companies

2021

阿帕鲁胺（Apalutamide）原料药 - 对仿制药公司极具吸引力的NCE-1机遇

Colloidal Iron Complex Formulations – Understanding and Developing the Process

2021

胶体铁络合物（Colloidal Iron Complex）配方 - 认识和发展流程

Dr. Reddy's Mirabegron API offering in both alpha and amorphous form

2021

瑞迪博士提供的阿尔法型和非晶型（Mirabegron） 原料药

Rivaroxaban from Dr.Reddy’s: Full basket offerings of API and Finished formulations

2021

瑞迪博士的利伐沙班（Rivaroxaban）： 完整的原料药和成品配方产品

Palbociclib – how a novel process development approach provides IP advantages

2021

帕博西尼（Palbociclib） - 新流程开发方法如何提供知识产权优势

Dr. Reddy's Elagolix API offering leverages a well rounded Quality by Design approach

2020

瑞迪博士的恶拉戈利（Elagolix ）原料药提供了全面的质量源于设计方法

Sacubitril/Valsartan (LCZ696) – Bringing yet another advantage through innovative API offerings

2020

沙库必曲/缬沙坦（Sacubitril/Valsartan）（LCZ696） - 通过创新的原料药产品带来另一个优势

Dr. Reddy’s Flow Chemistry experts share their perspectives in panel discussion of Chemistry Today

2020

瑞迪博士流动化学专家在《今日化学》（Chemistry Today）小组讨论会上分享了他们的观点

A closer look on how Dr. Reddy's met the stringent regulatory requirement of genotoxic impurities in Ranolazine

2020

进一步了解瑞迪博士如何满足雷诺嗪（Ranolazine）中基因毒性杂质的严格监管要求

Famotidine and Nizatidine APIs: NDMA controlled, customized particle distribution, supply chain security

2020

法莫替丁（Famotidine）和尼扎替丁（Nizatidine）原料药： 受控的亚硝基二甲胺（NDMA），定制的颗粒分布，安全的供应链

Sugammadex Sodium – The impact of an integrated understanding from API to formulation on injectable formulation success

2020

舒更葡糖钠（Sugammadex Sodium）- 从原料药到配方的综合理解对注射配方成功的影响

X

API
Active Pharmaceutical Ingredients

API Supplier of the Year

Global Generics & Biosimilars Awards 2021 winner for 3 consecutive years!

Explore our Products